Disease · MONDO_0016262

leiomyosarcoma of the corpus uteri

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. leiomyosarcoma of the corpus uteri. Diseases, record MONDO_0016262. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016262

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: leiomyosarcoma of the corpus uteri; Open Targets
Open Targets ID: MONDO_0016262; Open Targets
Other names: Uterine Leiomyosarcoma, body of uterus leiomyosarcoma, corpus uteri leiomyosarcoma, leiomyosarcoma - uterus, leiomyosarcoma of body of uterus, leiomyosarcoma of corpus uteri, leiomyosarcoma of the body of uterus, leiomyosarcoma of the uterine body, leiomyosarcoma of the uterine corpus, leiomyosarcoma of the uterus, leiomyosarcoma of uterine body, leiomyosarcoma of uterine corpus, leiomyosarcoma of uterus, uterine body leiomyosarcoma, uterine corpus leiomyosarcoma; Open Targets
Disease Ontology: DOID:5289; Disease Ontology
NCI Thesaurus: C6340; NCI Thesaurus
Orphanet: ORPHA:213625; Orphanet
Highest stage of its drugs: Phase 3, for 4 of its 21 drugs, from ClinicalTrials.gov; Open Targets

Drugs21

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
GEMCITABINE HYDROCHLORIDE	CHEMBL1637	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
OLAPARIB	CHEMBL521686	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
TEMOZOLOMIDE	CHEMBL810	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
TRABECTEDIN	CHEMBL450449	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
LETROZOLE	CHEMBL1444	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 21

See all 21 drugs

Targets52

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CSF1R	Macrophage colony-stimulating factor 1 receptor	2	Macrophage colony stimulating factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1436	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	2	Granulocyte colony stimulating factor receptor agonist	Phase 2	https://conductscience.org/library/genes/1441	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
KDR	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	2	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PARP1	PARP 1, 2 and 3	2	PARP 1, 2 and 3 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor	Phase 2/3	https://conductscience.org/library/genes/142	Drugs and targets
PARP2	PARP 1, 2 and 3	2	PARP 1, 2 and 3 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor	Phase 2/3	https://conductscience.org/library/genes/10038	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	2	Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5156	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	2	Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets

1 to 10 of 52

See all 52 targets

Trials20

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03565991	Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors	Phase 2	202	2023-08-07	Locally Advanced or Metastatic Solid Tumors, Genes, BRCA 1	AVELUMAB, TALAZOPARIB	Its record names the disease	ClinicalTrials.gov
NCT01012297	Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma	Phase 3	107	2017-07-14	Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Corpus Leiomyosarcoma	BEVACIZUMAB, DOCETAXEL, GEMCITABINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01533207	Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery	Phase 3	38	2020-04-06	Stage I Uterine Sarcoma AJCC v7, Uterine Corpus Leiomyosarcoma	DOCETAXEL, DOXORUBICIN HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00856050	Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma	Phase 2	27	2014-03-19	Leiomyosarcoma	LETROZOLE	Its record names the disease	ClinicalTrials.gov
NCT03880019	A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma	Phase 2	23	2023-09-21	Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Uterine Corpus Leiomyosarcoma	OLAPARIB, TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00379145	Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus	Phase 2	20	2017-12-12	Sarcoma	TRABECTEDIN	Its record names the disease	ClinicalTrials.gov
NCT01958580	Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery	Not applicable	3	2023-08-16	Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma, Stage IC Uterine Sarcoma, Stage IIA Uterine Sarcoma, Stage IIB Uterine Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Corpus Leiomyosarcoma	DOCETAXEL, GEMCITABINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT04969887	Combination Immunotherapy in Rare Cancers Under InvesTigation	Phase 2	240		Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm, MSI-H Solid Malignant Tumor	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT02249702	Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma	Phase 2	168		Leiomyosarcoma	DOCETAXEL, GEMCITABINE, TRABECTEDIN	Its record names the disease	ClinicalTrials.gov
NCT02131480	Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma	Phase 2	110		Uterus Leiomyosarcoma, Soft Tissue Leiomyosarcoma	DOXORUBICIN, TRABECTEDIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 20

See all 20 trials

Comparisons in its trials13

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Cohort 1 (BRCA 1/2 Defect) vs Cohort 2 (ATM Defect): Number of Participants With Positive Programmed Death Ligand 1 (PD-L1) Expression in Baseline Tumor Tissue	27 of 159	0 of 41	200	NCT03565991	Trial comparisons
Cohort 1 (BRCA 1/2 Defect) vs Cohort 2 (ATM Defect): deaths from any cause	15 of 159	3 of 41	200	NCT03565991	Trial comparisons
Cohort 1 (BRCA 1/2 Defect) vs Cohort 2 (ATM Defect): serious adverse events	50 of 159	7 of 41	200	NCT03565991	Trial comparisons
Arm I Gem+Doce+Placebo vs Arm II Gem+Doce+Bev: Frequency and Severity of Adverse Effects as Assessed by the CTCAE Version 4.0	36 of 54	46 of 53	107	NCT01012297	Trial comparisons
Arm I vs Arm II: serious adverse events	17 of 54	21 of 53	107	NCT01012297	Trial comparisons
Regimen 1 vs Regimen II: Number of Participants Who Experienced Death	5 of 20	1 of 18	38	NCT01533207	Trial comparisons
Regimen 1 vs Regimen II: Incidence of Grade 3 or Higher Adverse Events as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0	10 of 20	1 of 18	38	NCT01533207	Trial comparisons
Regimen 1 vs Regimen II: deaths from any cause	5 of 20	1 of 18	38	NCT01533207	Trial comparisons
Regimen 1 vs Regimen II: Number of Participants With Recurrence	8 of 20	8 of 18	38	NCT01533207	Trial comparisons
Regimen 1 vs Regimen II: serious adverse events	5 of 20	0 of 18	38	NCT01533207	Trial comparisons

1 to 10 of 13

See all 13 comparisons in its trials

Papers from its trials12

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21996263	RESULT	1	PubMed
18534250	RESULT	1	PubMed
12051882	RESULT	1	PubMed
41231502	DERIVED	1	PubMed
40608313	DERIVED	1	PubMed
37467452	DERIVED	1	PubMed
36394867	DERIVED	1	PubMed
34325109	DERIVED	1	PubMed
34298376	DERIVED	1	PubMed
33927108	DERIVED	1	PubMed

1 to 10 of 12

See all 12 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0016262

GET https://conductscience.org/api/diseases/v1/MONDO_0016262/drugs?page=2

API reference For AI assistants